A common feature of some advanced cancers is their enhanced capacity to metabolize glucose to lactic acid. Some carcinoma cells express highly glycolytic phenotype depending on the expression of hexokinase II in vitro and in vivo in some animal models.
Alkylating agent 3-BP apparently shows structural similarity to lactate, then the reactive 3-BP may enter cancer cells using the same transporter that exports lactate and then induce cancer cells ATP depletion followed by cell apoptosis.
is there any ongoing or recently finished experimental clinical trial using 3-BP as monotherapy or as a add on drug?
Prof. Dr. Thomas J. Vogl, administered 3-bromopyruvate (3BP) to a patient intra-arterially. Exploratory clinical trials may be going on.
A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside
Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL
J Bioenerg Biomembr. 2012; 44: 163-70.
This molecule has a short (77 minutes) half- life at physiological conditions.
The antitumor agent 3-bromopyruvate has a short half-life at physiological conditions. Glick M, Biddle P, Jantzi J, Weaver S, Schirch D.
Biochem Biophys Res Commun. 2014 Sep 12;452(1):170-3. doi: 10.1016/j.bbrc.2014.08.066. Epub 2014 Aug 21.
Full-text article: http://www.sciencedirect.com/science/article/pii/S0006291X14014892
J Bioenerg Biomembr. 2012 Feb;44(1):1-6. doi: 10.1007/s10863-012-9425-4.
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.
Pedersen PL.
Many thanks, Beatrice, for the reference. Pendersen & Ko are the original 3-BP investigators (2008-2012). Nevertheless, no other pre-clinical/clinical protocol has been published since. I am wondering if someone in the RG community is currently working w/the molecule. Matthew Vander Heiden has referenced that currently there are some similar molecules that act interfering cancer cell metabolism (e.g. 2-deoxyglucose, Dicholoroacetate, etc.), but again, there are no recent publications on this very interesting and potential cancer co-therapies. Let me know if you have any additional information or reference.
Rgds,
JAVR
Dear Dr Vargas,
Sorry to answer your question only after a year. I am the father of the patient, treated with 3BP by Prof Vogl. I think I can answer most of your questions, but would prefer to do so by private mail.
kind regards,
Harrie Verhoeven
Hola Jose Antonio: Mi hija Orene Cabot Moura, falleció el 21/09/2019, de cancer de hueso, antes de que pudiesemos experimentar con el 3-bromo piruvato. que conocimos a traves de la web:
http://selenitaconsciente.com/?p=232381
---------------------------------------------------------------------------------
https://www.kodiscovery.org/
.....Fundé una nueva empresa llamada K o D iscovery para seguir desarrollando 3BP como terapia anticancerígena. Espero ayudar a los pacientes que se han quedado sin opciones de tratamiento y a aquellos que desean ser tratados con 3BP como primera terapia. En última instancia, trabajaré en una miríada de proyectos de investigación adicionales asociados con enfermedades neurológicas, lesiones / heridas, infecciones, inflamación y otras afecciones de salud, para ayudar a los millones de personas afectadas por estas devastadoras afecciones.
Con gratitud, Young Ko
Hola Jose Antonio: Estoy muy interesado en el tema...estoy montando una web con datos sobre el 3-bromopiruvato.
https://3bromopiruvato.cat/index.html
https://3bromopiruvato.cat/
Un "informe de caso" de un estudio traslacional sobre la pequeña molécula "bloqueador de energía" 3-bromopiruvato (3BP) como potente agente anticancerígeno: del lado del banco a la cabecera
Article A translational study "case report" on the small molecule "e...
https://oncologiametabolica.com/protocolo-de-terapias-combinadas-de-oncologia-metabolica-cancer-integral-v1-0/
- Badges
- Science topic